Magnetic Resonance Imaging (MRI) Viability: Comparison of Myocardial Viability by Positron Emission Tomography and MRI
This study has been completed.
Sponsor:
Emory University
Information provided by (Responsible Party):
Randolph E Patterson, Emory University
ClinicalTrials.gov Identifier:
NCT00166179
First received: September 13, 2005
Last updated: September 25, 2014
Last verified: September 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to compare cardiac MRI with positron emission tomography (PET) with fluorodeoxyglucose (FDG) to determine if cardiac MRI images are as good as, or better, than PET with FDG.
| Condition |
|---|
|
Coronary Artery Disease |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Magnetic Resonance Imaging (MRI) Viability: Comparison of Myocardial Viability by Positron Emission Tomography and MRI |
Resource links provided by NLM:
Further study details as provided by Emory University:
Primary Outcome Measures:
- Magnetic Resonance Imaging (MRI) Viability: Comparison of Myocardial Viability by Positron Emission Tomography and MRI [ Time Frame: time of initial scans ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Compare size of regions of viable and non viable myocardium as % left ventricle by MRI vs. PET [ Time Frame: at time of initial scans ] [ Designated as safety issue: No ]
| Enrollment: | 57 |
| Study Start Date: | November 2003 |
| Study Completion Date: | October 2006 |
| Primary Completion Date: | October 2006 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years to 95 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Age > 25 yrs, mean + SD = 60.3 + 10.2, 83% male, are patients referred by cardiologist or cardiac surgeon for assessment of myocardial viability by PET FDG.
Criteria
Inclusion Criteria:
- PET-FDG ordered to assess myocardial viability
Exclusion Criteria:
- Contraindicated for MRI
- Pregnant
- Age <25 yrs
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00166179
Please refer to this study by its ClinicalTrials.gov identifier: NCT00166179
Locations
| United States, Georgia | |
| Crawford Long Hospital | |
| Atlanta, Georgia, United States, 30308 | |
Sponsors and Collaborators
Emory University
Investigators
| Principal Investigator: | Randolph Patterson, MD | Staff |
More Information
No publications provided
| Responsible Party: | Randolph E Patterson, Professor, Emory University |
| ClinicalTrials.gov Identifier: | NCT00166179 History of Changes |
| Other Study ID Numbers: | IRB00000292, 6-56550 |
| Study First Received: | September 13, 2005 |
| Last Updated: | September 25, 2014 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Emory University:
|
CAD |
Additional relevant MeSH terms:
|
Coronary Artery Disease Coronary Disease Myocardial Ischemia Arterial Occlusive Diseases |
Arteriosclerosis Cardiovascular Diseases Heart Diseases Vascular Diseases |
ClinicalTrials.gov processed this record on February 27, 2015